SOURCE: Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc.

November 18, 2015 09:00 ET

Plandai Biotechnology, Inc. Reaches Agreement With Deltamune to Study Commercial Potential of Phytofare in Livestock

Company Expects to Commence Clinical Trial in January 2016

LONDON, UNITED KINGDOM--(Marketwired - Nov 18, 2015) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) ("Plandaí" or "the Company"), producer of the highly bioavailable Phytofare® catechin complex, today announced that its wholly-owned subsidiary, Red Gold (Pty) Ltd., has reached an agreement with Deltamune (Pty) Ltd., a South African-based veterinary research and testing company that also develops and manufactures vaccines for treating Avian Influenza, Infectious Coryza, Egg Drop syndrome and Newcastle disease. Under the terms of the agreement, Deltamune will undertake clinical trials using Plandaí's Phytofare® Catechin Complex and Citrus Complex to determine the efficacy of the combined all-natural products in helping prevent diseases in poultry. Should the trials prove successful, the parties will move towards executing a production license and distribution agreement.

According to Plandaí, the initial investigations will take place at Deltamune approved research facilities in South Africa. Stage II studies will then be conducted at four different commercial poultry production locations in South Africa. The investigations will be monitored by both Deltamune and North West University's pharmacology department.

Roger Baylis-Duffield, Chief Executive Officer of Plandaí, commented, "Poultry diseases pose a huge risk to both farmers and the public, necessitating the use of vaccines and other synthetic treatment protocols in most commercial farms. The loss from both poultry mortality and the growth delays caused by the vaccines is staggering. With more consumers demanding an 'organic' solution that doesn't result in huge losses to the industry, we view Phytofare® as a potential game changer in animal husbandry."

"Green tea catechins and citrus limonoids," Mr. Duffield continued, "have demonstrably proven anti-viral and wellness properties. The Deltamune trials are designed to show that adding these all-natural products to the animals' food source can reduce the mortality rates and increase farm yields. By entrapping the product in Pheroid®, we should have a delivery system that provides tremendous bioavailability and allows us to offer a therapeutic dose for the animals in a safe, natural way. The economic potential for this product is tremendous. Billions of dollars are wasted annually not just on the vaccines, but also in the delays in growth caused by such vaccines. That these vaccines could potentially find residency in the meat and eggs is also of concern to consumers. 

"In many parts of the world, chickens are subjected to a chlorine bath after slaughter to kill remaining pathogens -- a practice banned in Europe but still prevalent in the U.S. One part of the Deltamune study is designed to test if a Phytofare®/Pheroid® bath is an equally efficacious but safe and natural alternative. If successful, this new protocol will help prevent the spread of disease while eliminating the use of more chemicals in our food stream."

The Company announced that, pending approval from the South Africa ethics committee, the clinical trials should commence in January 2016 and take approximately 60 days to complete.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at

Contact Information